Literature DB >> 26320688

Lariciresinol-4-O-β-D-glucopyranoside from the root of Isatis indigotica inhibits influenza A virus-induced pro-inflammatory response.

Jing Li1, Beixian Zhou2, Chufang Li1, QiaoYan Chen3, Yutao Wang1, Zhengtu Li4, Tingting Chen4, Chunguang Yang4, Zhihong Jiang2, Nanshan Zhong5, Zifeng Yang6, Rongchang Chen7.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Isatis indigotica is a traditional Chinese medicine. Its dried roots named "ban lan gen" in Chinese, are used for clinical treatment of virus infection, tumor, inflammation with a long history. However, its anti-influenza active ingredient and the underlying mechanism remain unclear. In this study, the anti-influenza and anti-inflammatory effects of a lignan glycoside: lariciresinol-4-O-β-D-glucopyranoside isolated from the root of I. indigotica on human alveolar epithelial cell line A549 infected with influenza A virus were investigated.
MATERIALS AND METHODS: Chemical and spectroscopic methods were employed to identify the structure of the lignan glycoside. Cytotoxicity of the lignan glycoside was analyzed using methylthiazolyltetrazolium (MTT) assay. The inhibitory activity against influenza virus of the lignan was determined by CPE inhibition assay. HEK-293 cells stably co-transfected with NF-κB responsive firefly luciferase and constitutively expressing GFP were employed for monitoring the effect of the lignan on NF-κB signal pathway activation. Nuclear export of viral ribonucleoprotein (RNP) complexes was monitored by indirect immunofluorescence. Quantitative real-time PCR was used to quantify the expression profiling of cytokines and chemokines after infection with influenza virus.
RESULTS: We showed that the lignan glycoside treatment was effective against the influenza A virus-induced cytopathic effect (CPE) in MDCK cells. Further study demonstrated the lignan glycoside attenuated virus-induced NF-κB activation, but did not affect export of viral ribonucleoprotein (RNP) complexes from the nucleus in late stages of infection. We revealed that the lignan glycoside suppressed influenza A virus (H1N1)-induced expression of the pro-inflammatory molecules IL-6, TNF-α, IL-8, MCP-1, IP-10 and IFN-α. Moreover, the cytokines and chemokines profiles induced by H9N2 virus resembled those of influenza virus H1N1, but the lignan glycoside reduced the expression of IP-10 and TNF-α.
CONCLUSIONS: Our results suggest that the lignan glycoside is a bioactive component of I. indigotica which may contribute an adjunct to pharmacotherapy for influenza virus infection.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  45027869; Inflammation; Influenza virus; Lariciresinol-4-O-β-D-glucopyranoside; PubChem CID:; Root of Isatis indigotica

Mesh:

Substances:

Year:  2015        PMID: 26320688     DOI: 10.1016/j.jep.2015.08.037

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  24 in total

Review 1.  Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies.

Authors:  Zhengtu Li; Li Li; Shuai Zhao; Jing Li; Hongxia Zhou; Yunhui Zhang; Zifeng Yang; Bing Yuan
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Functional Characterization of UDP-Glycosyltransferases Involved in Anti-viral Lignan Glycosides Biosynthesis in Isatis indigotica.

Authors:  Yuping Tan; Jian Yang; Yinyin Jiang; Jian Wang; Yahui Liu; Yujun Zhao; Baolong Jin; Xing Wang; Tong Chen; Liping Kang; Juan Guo; Guanghong Cui; Jinfu Tang; Luqi Huang
Journal:  Front Plant Sci       Date:  2022-06-14       Impact factor: 6.627

3.  Dynamic metabolic and transcriptomic profiling of methyl jasmonate-treated hairy roots reveals synthetic characters and regulators of lignan biosynthesis in Isatis indigotica Fort.

Authors:  Lei Zhang; Junfeng Chen; Xun Zhou; Xiaofei Chen; Qing Li; Hexin Tan; Xin Dong; Ying Xiao; Langdong Chen; Wansheng Chen
Journal:  Plant Biotechnol J       Date:  2016-06-23       Impact factor: 9.803

4.  AP2/ERF Transcription Factor, Ii049, Positively Regulates Lignan Biosynthesis in Isatis indigotica through Activating Salicylic Acid Signaling and Lignan/Lignin Pathway Genes.

Authors:  Ruifang Ma; Ying Xiao; Zongyou Lv; Hexin Tan; Ruibing Chen; Qing Li; Junfeng Chen; Yun Wang; Jun Yin; Lei Zhang; Wansheng Chen
Journal:  Front Plant Sci       Date:  2017-08-04       Impact factor: 5.753

5.  Antiviral activity of shikonin ester derivative PMM-034 against enterovirus 71 in vitro.

Authors:  Y Zhang; H Han; L Sun; H Qiu; H Lin; L Yu; W Zhu; J Qi; R Yang; Y Pang; X Wang; G Lu; Y Yang
Journal:  Braz J Med Biol Res       Date:  2017-08-17       Impact factor: 2.590

6.  Transcriptome profiling of influenza A virus-infected lung epithelial (A549) cells with lariciresinol-4-β-D-glucopyranoside treatment.

Authors:  Beixian Zhou; Jing Li; Xiaoli Liang; Zifeng Yang; Zhihong Jiang
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

Review 7.  Plant-derived lignans as potential antiviral agents: a systematic review.

Authors:  Xin-Ya Xu; Dong-Ying Wang; Yi-Ping Li; Stephen T Deyrup; Hong-Jie Zhang
Journal:  Phytochem Rev       Date:  2021-05-31       Impact factor: 7.741

8.  Stereospecific Assay of (R)- and (S)-Goitrin in Commercial Formulation of Radix Isatidis by Reversed Phase High-Performance Liquid Chromatography.

Authors:  Lixing Nie; Zhong Dai; Shuangcheng Ma
Journal:  J Anal Methods Chem       Date:  2017-08-15       Impact factor: 2.193

9.  Chinese herbal medicine compound Yi-Zhi-Hao pellet inhibits replication of influenza virus infection through activation of heme oxygenase-1.

Authors:  Jinqiu Yin; Linlin Ma; Huiqiang Wang; Haiyan Yan; Jin Hu; Wen Jiang; Yuhuan Li
Journal:  Acta Pharm Sin B       Date:  2017-06-20       Impact factor: 11.413

Review 10.  The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic?

Authors:  Andréa D Fuzimoto; Ciro Isidoro
Journal:  J Tradit Complement Med       Date:  2020-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.